Report
Damien Choplain ...
  • Martial Descoutures

Valneva : Ixchiq struggling – full-year guidance adjusted

>Top line in line and EBITDA higher than expected – Disappointment on Ixchiq - Valneva reported 9M 2024 results in line with expectation for sales (+0%) and above the css for adjusted EBITDA (+13%). Product sales rose 6% to € 110.4m (+2% vs css) driven by Ixiaro (+31%, +4% vs css) and Dukoral (+6%, +10% vs css) boosted in Q3 (+85%) by the pick-up in marketing outlays. The disappointment in this release came from the performance of Ixchiq which is struggling to get goi...
Underlying
Valneva SE

Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Damien Choplain

Martial Descoutures

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch